BEQVEZ (fidanacogene elaparvovec)
TherapyPfizer
BEQVEZ (fidanacogene elaparvovec) from Pfizer is a gene therapy designed for eligible adults with hemophilia B.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and BEQVEZ. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where BEQVEZ is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Moderate to severe Hemophilia B patients Non-cancer · Blood | AAV Antibodies
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for BEQVEZ.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering BEQVEZ for eligible patients.
Test
nAbCyte Anti-AAVRh74var HB-FE Assay
Labcorp
Method
AAV_Antibody
Specimen
Serum
1 approvalView test profile →